What are the best pharmaceutical leading stocks?
Leading stocks in the pharmaceutical industry refer to publicly traded companies that have a leading position and influence in the pharmaceutical field. These companies have innovative drug development capabilities, broad product lines and strong market share. They are committed to advancing medical technology and providing safe, The following is a ranking of the leading pharmaceutical stocks which are the best, which is of great benefit to all of you, take a look together.
Which leading pharmaceutical stocks are the best?
Domestic generic drug leading stocks: Hengrui Pharmaceuticals, Huadong Pharmaceuticals, Huahai Pharmaceuticals, Primavera Pharmaceuticals, Jingxin Pharmaceuticals, Xinlitai.
Top 10 Leading Stocks in Pharmaceutical Sector
The top 10 leading stocks in the pharmaceutical sector are Hengrui Medicine, Fosun Pharmaceuticals, Coren Pharmaceuticals, Health Yuan, Renfo Pharmaceuticals, Hesco, Hualan Biologicals, Ankor Biologicals, Myriad Medical, and Kaili Medical.
The leading stock refers to a certain period in the stock market speculation on other stocks in the same industry sector has the influence and appeal of the stock, and its rise and fall is often on other stocks in the same industry sector to guide the rise and fall and demonstration effect. Leading stocks are not static, and their status often only lasts for a period of time. The basis for becoming a leading stock is that any information related to a particular stock is immediately reflected in the stock price.
China's securities market stocks, excluding those that have been specially handled A shares of the up and down range of 10% as a limit, when the day's increase reached 10% limit for the upper limit, the buyers continue to maintain to the close, said the stock for the up and down range of the ST class of shares is set at 5%, up to 5% that is, the up and down range of the up and down range of the up and down range of the up and down range of the up and down range of the up and down range of the up and down range, to reach 5%. The stop, is the day the price stops rising, rather than stop trading.
The up/down range is a description of the up/down value, expressed in %, up/down range = up/down value/yesterday's close_100%. The value resulting from comparing the latest traded price (or closing price) of the current trading day with the closing price of the previous trading day, which is generally expressed as a percentage. In the Chinese stock market to stop to make restrictions, so there is a "stop" said.
The closing price refers to the closing price of the stock market, the last transaction of the day for the securities of the last minute before the volume-weighted average price of all transactions (including the last transaction). No transaction on the day, the previous closing price for the day's closing price. The closing price of the disk feedback is the closing after the stay on the disk of the pending status, including 10 bid and ask price and the corresponding number of pending orders.
Shares are part of the ownership of the joint-stock company, but also issued ownership certificates, is the joint-stock company to raise funds issued to the shareholders as a shareholding certificates and through the acquisition of dividends and bonuses of a marketable security. Stock is a long-term credit instrument in the capital market, which can be transferred, bought and sold, and by virtue of which the shareholders can share the profits of the company, but also have to bear the risks brought about by the company's operational errors. Each share of stock represents a basic unit of shareholder ownership in the corporation. Every public company issues shares.
What are the leading stocks of traditional Chinese medicine stocks
1, Tongrentang (600085): leading stocks of traditional Chinese medicine.October 22 news, Tongrentang as of 15:00, the stock rose 0.61%, at 33.11 yuan; the stock price fell 1.06% in 5 days, the market value of 45.409 billion yuan.
The company has been listed for more than 10 years of growth and development, has formed to the core of the manufacturing of proprietary Chinese medicines, with the planting of Chinese herbal medicines, research and development of proprietary Chinese medicines, pharmaceutical logistics and distribution, pharmaceutical retailing of a more complete industrial chain.
2, Baiyunshan (600332): leading stocks of traditional Chinese medicine. October 22 news, Baiyunshan 5-day share price fell 0.5%, up 1.71% this year, the latest 29.8 yuan, the price-earnings ratio of 16.62.
Company is the domestic traditional Chinese medicine industry with the most varieties of the most complete, the largest number of Chinese old brand, the largest value of traditional Chinese medicine enterprises, traditional Chinese medicine varieties of more than 400 kinds, covering almost all of the traditional Chinese medicines. There are more than 400 kinds of traditional Chinese medicines, covering almost all traditional Chinese medicine classifications, 45 kinds of national Chinese medicine secondary protection varieties, of which more than 20 are exclusive production varieties, and there are more than 100 kinds of foreign brand-name pharmaceutical products exclusively represented by the company. Such as Wang Lao Ji, Chen Li Ji, Pan Gao Shou, Jing Xiu Tang, etc., all of which are long-established century-old stores. These include 20 exclusive products such as Quenching Thirst Pills and Hua Tuo Zaizao Pills. Wanglaoji Herbal Tea, Baoji Pills, Wu Ji Bai Feng Pills and other products are well-known in South China and Southeast Asia. After five enterprises of the company, including Wanglaoji Pharmaceuticals and Jingxiutang Pharmaceuticals, were selected as the first batch of "old Chinese brands", three enterprises, including Zhongyi Pharmaceuticals, were selected as the second batch of "old Chinese brands".
3, Pientzehuang (600436): leading stock of traditional Chinese medicine. on October 22, opening news, Pientzehuang latest reported 434.99 yuan, turnover 3.01 million lots, total market value is 262.437 billion yuan.
The company was awarded the title of "high-tech enterprise" by the Ministry of Science and Technology of China, and passed the re-recognition of high-tech enterprise, and was evaluated as "Top 10 Chinese Traditional Medicine Enterprises with Scientific and Technological Innovation Output in 2015".
The other traditional Chinese medicine conceptual stocks are as follows: Tianyin Pharmaceuticals, JiuDian Pharmaceuticals, Erkang Pharmaceuticals, Qian Qian Pharmaceuticals. The company's main business is the development of a new product line, which will be launched in the next few years.
What are the leading high-quality pharmaceutical stocks?
cxo Pharmaceutical leading stocks are: WuXi AppTec, Medicilon, Zhaoyan New Drugs, Kanglong Huacheng, Kelaiyin, Tigermed collection and so on.
The stock market cxo generally refers to the pharmaceutical R & D and production outsourcing enterprises, which includes CRO/CMO/CDMO, that is, contract research and development services organization, contract manufacturing business organization cxo pharmaceutical leading stocks are Medici, Zhaoyan New Drugs, Kanglong Huacheng, WuXi Kangde, and Tigermed Pharmaceuticals.
1. WuXi AppTec (603259): clinical side CRO/CDMO enterprise leader. WuXi AppTec (stock code: 603259.SH/2359.HK) provides a full range of integrated new drug development and manufacturing services for the global biopharmaceutical industry. By empowering global pharmaceutical, biotechnology and medical device companies, WuXi AppTec is committed to advancing the process of new drug discovery and development to bring breakthrough therapeutic solutions to patients. With research-first and customer-centered approach, WuXi AppTec helps its customers improve their R&D efficiency through cost-effective and efficient R&D services covering chemical drug R&D and manufacturing, cell and gene therapy R&D and manufacturing, and medical device testing.
2. Kanglong Huacheng (300759):Clinical side of the CRO enterprise dragon two. Kanglong Huacheng (Beijing) New Drug Technology Co. The company is a wholly owned U.S. enterprise established in 2003, providing comprehensive drug preclinical R&D services for global pharmaceutical companies and biopharmaceutical R&D organizations.
3. Zhaoyan New Drug (603127): clinical side CRO enterprises, segmentation leader. Beijing Zhaoyan New Drug Research Center Co., Ltd. was registered in the Development Zone Branch on 1998-02-25. Legal representative Feng Yuxia.
On November 26, 2019, it was selected to the list of 2019 National Small and Medium-sized Enterprises Public **** Service Demonstration Platforms.
4.Medicine Stone Technology (300725): clinically-side CRO company, segmented into Tiger Pharmaceuticals Revenue CAGR of 27.24%. Nanjing Medicine Stone Technology Co., Ltd. in December 26, 2006 in the Nanjing Municipal Administration for Industry and Commerce, Nanjing High-tech Industrial Development Zone Branch was registered. Legal representative Yang Minmin, the company's scope of business includes technology development, technical consulting, technical services in the field of biomedical expertise.
What are the leading stocks in the pharmaceutical industry
1, Hengrui Medicine
Jiangsu Hengrui Medicine Co., Ltd. is approved by the People's Government of Jiangsu Province, by the Lianyungang Hengrui Group Co., Ltd. and other five initiators in April 1997 *** with the initiation of the establishment of the limited liability company, is the largest anti-tumor It is the largest research and production base of anti-tumor drugs in China.
2, East China Pharmaceutical
Hangzhou East China Pharmaceutical Group Company formerly known as Zhejiang Pharmaceutical Factory, founded in 1952, later renamed Hangzhou Second Pharmaceutical Factory, Hangzhou East China Pharmaceutical Factory.
On December 16, 1992, Hangzhou Huadong Pharmaceutical Group Company was established on the basis of Hangzhou Huadong Pharmaceutical Factory, which has developed into a joint-stock enterprise--Huadong Pharmaceuticals Co., Ltd. and four Sino-foreign equity joint ventures (Hangzhou Zhongmei Huadong Pharmaceutical Co.) and more than 10 other holding pharmaceutical enterprises.
3, Huahai Pharmaceutical
Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989, its predecessor is Linhai City flood bridge synthetic chemical plant, in January 2001, the whole change was set up for the establishment of Zhejiang Huahai Pharmaceutical Company Limited.
3, the company's shares were successfully listed on the Shanghai Stock Exchange. Stock abbreviation: Huahai Pharmaceuticals, stock code: 600521.
4, Puli Pharmaceutical
Hainan Puli Pharmaceuticals Co., Ltd. was founded in 1992, is specialized in the research and development of chemical pharmaceutical preparations, production and sales of high-tech enterprises, has been through the China's pharmaceutical enterprises internationalization of the preparations of the pilot enterprise certification. The company has two wholly-owned subsidiaries, Zhejiang Puli Pharmaceutical Co., Ltd. and Hangzhou Saili Pharmaceutical Research Institute.
5, Jingxin Pharmaceutical
Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974, has developed into a national key high-tech enterprises, China's top 100 pharmaceutical companies, in July 2004, successfully listed on the Shenzhen Stock Exchange.
6, Xinlitai
Shenzhen Xinlitai Pharmaceutical Co., Ltd. is approved by the Ministry of Commerce of the People's Republic of China *** and the Ministry of Commerce "Ministry of Commerce on the consent of Shenzhen Xinlitai Pharmaceutical Co., Ltd. restructuring into a sino-foreign equity joint venture approved by the Ministry of Commerce" (business capital approval [2007] No. 1016), and to obtain the Ministry of Commerce issued by the "People's Republic of China *** and the State of Taiwan, Hong Kong and Macao investment enterprises approved certificate", in June 2007, in the Ministry of Commerce of the People's Republic of China and the State of Taiwan, Hong Kong and Macao investment enterprises approved certificate. Certificate" issued by the Ministry of Commerce, on June 29, 2007 by the Shenzhen Xinlitai Pharmaceutical Company Limited (hereinafter referred to as "Shenzhen Xinlitai") was established in accordance with the overall changes in the establishment of foreign-invested joint-stock companies, with a registered capital of 85 million yuan, and at the same time received the business license of the enterprise legal person, Registration No. 440301501124347.